Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

X D Luo

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|October 10, 2019
[Analysis of changes in clinical characteristics and laboratory indexes of 54 cases of acute fatty liver of pregnancy]M Zhou, X D Luo, Y Yang
[Zhonghua Yan Ke Za Zhi] Chinese Journal of Ophthalmology|August 26, 2020
[Intra-retinal vein cannulation without tissue-type plasminogen activator for hemi-central retinal artery occlusion]C Zhang, X D Luo, X X Li
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|October 24, 2017
[Clinical effect of 156-week telbivudine sequential therapy in HBeAg-positive chronic hepatitis B patients with suboptimal response to pegylated interferon-α-2a therapy]X D Luo, X P Chen, X F Chen
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|January 12, 2018
[Optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B after suboptimal response to 24 weeks of Peg-IFN α-2a]X D Luo, X P Chen, X F Chen
Sheng Li Ke Xue Jin Zhan [Progress in Physiology]|May 25, 2001
[A new signal receptor family--a review of the current progress of Toll/IL-1R family]J Chen, X D Luo, Z C Yang, et al.
Journal of Asian Natural Products Research|July 26, 2006
A new naphthaquinone derivative from Chirita eburneaX-H Cai, X-D Luo, J Zhou, et al.
Journal of Viral Hepatitis|October 31, 2017
Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trialX D Luo, X F Chen, Y Zhou, et al.
Fitoterapia|November 15, 2000
A new triterpenoid from Azadirachta indicaX D Luo, S H Wu, Y B Ma, et al.
Phytochemistry|May 5, 2001
ent-Pimarane derivatives from Dysoxylum hainanenseX D Luo, S H Wu, Y B Ma, et al.
Phytochemistry|October 3, 2000
Tirucallane triterpenoids from Dysoxylum hainanenseX D Luo, S H Wu, Y B Ma, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|October 10, 2019
[Analysis of changes in clinical characteristics and laboratory indexes of 54 cases of acute fatty liver of pregnancy]M Zhou, X D Luo, Y Yang
[Zhonghua Yan Ke Za Zhi] Chinese Journal of Ophthalmology|August 26, 2020
[Intra-retinal vein cannulation without tissue-type plasminogen activator for hemi-central retinal artery occlusion]C Zhang, X D Luo, X X Li
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|October 24, 2017
[Clinical effect of 156-week telbivudine sequential therapy in HBeAg-positive chronic hepatitis B patients with suboptimal response to pegylated interferon-α-2a therapy]X D Luo, X P Chen, X F Chen
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|January 12, 2018
[Optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B after suboptimal response to 24 weeks of Peg-IFN α-2a]X D Luo, X P Chen, X F Chen
Sheng Li Ke Xue Jin Zhan [Progress in Physiology]|May 25, 2001
[A new signal receptor family--a review of the current progress of Toll/IL-1R family]J Chen, X D Luo, Z C Yang, et al.
Journal of Asian Natural Products Research|July 26, 2006
A new naphthaquinone derivative from Chirita eburneaX-H Cai, X-D Luo, J Zhou, et al.
Journal of Viral Hepatitis|October 31, 2017
Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trialX D Luo, X F Chen, Y Zhou, et al.
Fitoterapia|November 15, 2000
A new triterpenoid from Azadirachta indicaX D Luo, S H Wu, Y B Ma, et al.
Phytochemistry|May 5, 2001
ent-Pimarane derivatives from Dysoxylum hainanenseX D Luo, S H Wu, Y B Ma, et al.
Phytochemistry|October 3, 2000
Tirucallane triterpenoids from Dysoxylum hainanenseX D Luo, S H Wu, Y B Ma, et al.
Pageof 3